First Manhattan Co. lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,376,228 shares of the company’s stock after selling 68,407 shares during the quarter. Johnson & Johnson comprises approximately 1.8% of First Manhattan Co.’s investment portfolio, making the stock its 7th biggest holding. First Manhattan Co. owned 0.09% of Johnson & Johnson worth $332,007,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $106,000. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $124,000. Lenox Wealth Management Inc. boosted its holdings in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares in the last quarter. Intercontinental Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $200,000. Finally, Legacy Advisors LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $202,000. Institutional investors own 67.23% of the company’s stock.
Several research analysts have recently issued reports on the stock. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a report on Thursday, January 11th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Jefferies Group set a $161.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, March 23rd. Finally, TheStreet cut shares of Johnson & Johnson from an “a” rating to a “c+” rating in a report on Monday, March 26th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $144.58.
Shares of NYSE:JNJ opened at $128.10 on Monday. The company has a market cap of $343,679.78, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. Johnson & Johnson has a 1-year low of $120.95 and a 1-year high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the firm posted $1.58 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “First Manhattan Co. Has $332.01 Million Holdings in Johnson & Johnson (JNJ)” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3342664/first-manhattan-co-has-332-01-million-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.